Characterization of Epilepsy Patients BEEP 2b (BEEP2b)

Food and Drug Administration (FDA)

Status and phase

Completed

Phase 1

Conditions

Epilepsy

Treatments

Drug: Lamotrigine (brand name vs generic drugs)

Drug: Oxcarbazepine (brand name vs generic drugs)

Drug: Carbamazepine (brand name vs generic drugs)

Drug: Topiramate (brand name vs generic drugs)

Drug: Divalproex Sodium (brand name vs generic drugs)

Drug: Zonisamide (brand name vs generic drugs)

Drug: Phenytoin sodium (brand name vs generic drugs)

Drug: levetiracetam (brand name vs generic drugs)

Study type

Interventional

Funder types

Other

Other U.S. Federal agency

Identifiers

NCT02707965

HHSF223201400188C (Other Grant/Funding Number)

15-107D

Details and patient eligibility

About

Some epilepsy patients are described as GB when they have worsened seizures or side effects related to switching between brand name and generic, or between generic antiepileptic drug (AED) products. In concert with Aim 1 (protocol BEEP2a), this study will uncover possible reasons for patient problems with the drug switching. Factors that will be studied in GB epilepsy patients include physiologic, psychological, and genetic factors, including in this protocol whether brand and generic AEDs are pharmacokinetically similar in GB individuals.

Full description

This pilot study is exploratory research to characterize the "generic brittle" (GB) patient and to identify major causes for generic brittleness in epilepsy patients who are sensitive to antiepileptic drug (AED) formulation changes.

The primary aim of this BEEP2b study is to perform individual pharmacokinetic (PK) similarity testing of brand and generic AEDs in "probably GB" patients (N=12),who were selected on the basis of having GB-defining factors from the BEEP2a study, in order to confirm whether these factors are predictive of a generic brittle response to product switching. The study design involves a randomized, double-blind, multiple-dose, complete four-way replicate crossover design in which one brand and one generic will be compared in each patient from the patient's own AED regimen. Associated adverse events (i.e. seizures and side effects) will also be assessed. Bioequivalence (BE) will not be assessed. Rather, about nine AEDs are expected to be collectively evaluated. Generic brittleness anticipates that, for individual subjects, brand and generic may be the same or different, depending upon the underlying basis for generic brittleness. This exploratory research is focused on understanding individual patient attributes that contribute to GB, and is not focused on either product development or comparison of specific products.

Enrollment

21 patients

Sex

All

Ages

18 to 76 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject previously completed BEEP2a study, found to be probably GB, and able to provide informed consent or subject's legally authorized representative is able to provide informed consent.
Subject is male or female between 18 and 76 years of age inclusive.
Subject has a diagnosis of epilepsy including focal or primary generalized epilepsy.
Subject is taking at least one study antiepileptic drug for the treatment of epilepsy.
Subject is an acceptable candidate for venipuncture.
Subject is willing to be switched between brand and generic drug.
Subject is willing to stop all non-routine OTC medications for 24 hours prior to and during pharmacokinetic study visits.
Subject is willing to maintain stable doses of all other AEDs, including Vagus Nerve Stimulation parameters for the duration of the study.

Exclusion criteria

Subject has any medical condition, including a progressive neurological condition, which in the opinion of the investigator, could jeopardize the subject's health or would compromise the subject's ability to participate in the trial.
Subject has a history of alcohol or drug abuse, which in the opinion of the investigator, could jeopardize the subject's health or would compromise the subject's ability to participate in this trial.
Subject has a history of previous or current significant psychiatric disorder that would interfere with conduct of the study.
Subject is pregnant or lactating.
Subject has severe liver impairment as assessed by alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels ≥10 times the upper limit of normal (ULN).
Subject has severe renal impairment as assessed by creatinine clearance lower than 30mL/min, using the Cockcroft-Gault formula.
Female subjects of childbearing potential will not be eligible to participate who are unwilling or unable to use a medically acceptable method of contraception throughout the entire study period and for one week after the study is completed. Medically acceptable methods of contraception that may be used by the subject and/or her partner are: condom with spermicide, diaphragm with spermicide, IUD without progesterone, vaginal spermicidal suppository, surgical sterilization of their partner(s) or abstinence.
Subject is not willing or able to be adherent to study protocol (e.g. study medication dosing and any interacting comedication).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

21 participants in 2 patient groups

Sequence 1

Active Comparator group

Description:

This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.

Treatment: